Cost-Effectiveness of Zanubrutinib Versus Bendamustine and Rituximab in Patients With Untreated Chro...
Cost-Effectiveness of Zanubrutinib Versus Bendamustine and Rituximab in Patients With Untreated Chronic Lymphocytic Leukemia
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Highlights•The incidence of chronic lymphocytic leukemia (CLL) in China is on the rise. •Zanubrutinib seems to be an attractive option for the treatment of untreated CLL. •The economic burden is substantial, and related research holds significant value. •To our knowledge, this is the first study to assess the economic evaluation of zanubrutinib in...
Alternative Titles
Full title
Cost-Effectiveness of Zanubrutinib Versus Bendamustine and Rituximab in Patients With Untreated Chronic Lymphocytic Leukemia
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_3106460008
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3106460008
Other Identifiers
ISSN
0149-2918,1879-114X
E-ISSN
1879-114X
DOI
10.1016/j.clinthera.2024.08.016
